Cosentyx (secukinumab) / Novartis - LARVOL DELTA

Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study. (PubMed, Dermatology) - "Both TNF-α and IL-17 inhibitors demonstrate rapid onset of action in HS. However, IL-17 inhibitors may offer superior mid-term durability of response, supporting their role as a preferred option for sustained disease control."

HEOR • Journal • Real-world evidence • Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Oncology • IL17A

On 17 September 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Cosentyx. The marketing authorisation holder for this medicinal product is Novartis Europharm Limited. (European Medicines Agency) - "The CHMP adopted a new indication as follows...Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy....Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents...indicated for the treatment of active moderate to severe hidradenitis suppurativa...treatment of active psoriatic arthritis in adult patients...Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)...Non-radiographic axial spondyloarthritis (nr-axSpA)...indicated for the treatment of active enthesitis-related arthritis...alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older..."

CHMP • Hidradenitis Suppurativa • Idiopathic Arthritis • Immunology • Plaque Psoriasis • Psoriatic Arthritis • Spondylarthritis

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) in polymyalgia rheumatica (PMR) (GlobeNewswire) - "The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper. If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for people living with PMR, a disease with very limited advanced treatment options....The positive CHMP opinion is supported by results from the pivotal REPLENISH Phase III trial in which all primary and secondary endpoints were met across both Cosentyx 300mg and 150mg treatment arms, including complete sustained remission and time until patients needed additional treatment through week 52....Following the CHMP recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months."

CHMP • EMA approval • Polymyalgia Rheumatica

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Differential Risk of Paradoxical Alopecia between Secukinumab and Ixekizumab: A Comparative Pharmacovigilance Analysis Using EudraVigilance and FAERS Database (EADV 2026) - No abstract available

Adverse events • Alopecia • Immunology

Comparative Pancreatitis Safety Signal of IL-17 Versus IL-23 Inhibitors: A FAERS Pharmacovigilance Study (ACG 2026) - "Reports containing the preferred term âpancreatitisâ were identified for IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) and IL-23 inhibitors (guselkizumab, risankizumab, tildrakizumab). 707 cases of pancreatitis were reported. Among IL-17 inhibitors, 385 reports were associated with secukinumab, 43 with ixekizumab, and 19 with bimekizumab. Secukinumab demonstrated a significant disproportionality signal [ROR 1.379 (95% CI 1.248â1.525); PRR 1.378; ϲ 39.8; p< 0.05]."

Adverse events • Clinical • Immunology • Inflammation • Inflammatory Arthritis • Pancreatitis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • IL17A • IL23A • ROR1

When anti-tumor necrosis factor-α backfires: paradoxical psoriasis and psoriatic arthritis in a patient with hidradenitis suppurativa. (PubMed, Dermatol Reports) - "Recently, interleukin (IL)-17 inhibitors (secukinumab, bimekizumab) were also approved in Europe for moderate-to-severe HS. We report a case of paradoxical inverse psoriasis and suspected early psoriatic arthritis induced by adalimumab in an HS patient, successfully managed by switching to secukinumab. [...]."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TNFA

Histological findings in new onset colitis associated with IL-17a inhibitor therapy (ECP 2026) - " In total, IL-17a inhibitor-associated colitis was the favoured diagnosis for 16 patients, 9 men and 7 women aged 24-75 years (mean 49.4) who received IL-17a inhibitors (secukinumab 10/16, ixekizumab 5/16, bimekizumab 1/16) for various indications, most commonly psoriatic arthritis (8/16). The morphological range of IL-17a inhibitor therapy-associated colitis is wide and may be hard to distinguish from IBD, particularly when drug history is unknown. In patients with de novo gastrointestinal inflammation after introduction of IL-17a inhibitor treatment, cessation of the drug may lead to full histological remission."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Secukinumab Demonstrates Consistent Clinical Efficacy in Patients with Psoriatic Arthritis and Elevated BMI and Associated Comorbidities (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Mechanistic study of IL-17 inhibitors in alleviating inflammation in ankylosing spondylitis by regulating Treg cell function through modulation of the Ahr signaling pathway. (PubMed, Hum Cell) - "A proteoglycan (PG)-induced mouse model of AS, comprising a control group, a model group (PG), and an IL-17 inhibitor treatment group (PG + Secukinumab), was established...In conclusion, the IL-17 inhibitor alleviated AS inflammation by activating the Ahr signaling pathway and enhancing Treg cell function, thus correcting immune imbalance. This study reveals a novel "IL-17 inhibitor-Ahr-Treg" immune regulatory axis, providing novel insights into immunotherapy for AS."

IO biomarker • Journal • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL10 • IL17A • IL6 • TGFB1 • TNFA

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update. (PubMed, J Dermatolog Treat) - "For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options. These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients."

Clinical guideline • Journal • Review • Dermatology • Immunology • Oncology • Pediatrics • Psoriasis • IL12A • IL23A

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. (PubMed, J Dermatolog Treat) - "In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients. Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent."

Journal • Review • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL23A • TNFA

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "For palmoplantar psoriasis, secukinumab ranked highest (SUCRA = 79.7%), followed by bimekizumab (72.2%) and ustekinumab (69.7%)...For scalp psoriasis, brodalumab (87.7%) and ixekizumab (86.9%) ranked highest, followed by bimekizumab (69.0%) and guselkumab (65.1%); the brodalumab estimate relied on a single contributing study...Bimekizumab and ixekizumab showed consistently favorable rankings across sites, but treatment selection should consider certainty of evidence, sensitivity analyses, long-term response, and patient-level factors. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251271255."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series. (PubMed, Int J STD AIDS) - "Psoriasis Area Severity Index (PASI) scores, CD4 cell counts, HIV RNA levels, treatment duration and adverse events were obtained from medical records.ResultsThree patients received secukinumab and one received ixekizumab. No adverse events were observed during follow-up.ConclusionAnti-IL-17 therapy was associated with clinical improvement without observed deterioration in immunological or virological parameters in this small case series. Larger prospective studies are required before conclusions regarding safety can be drawn."

Journal • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis • CD4 • IL17A

Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study. (PubMed, J Inflamm Res) - "Secukinumab demonstrated meaningful 16-week efficacy and favorable safety in Chinese patients with moderate-to-severe HS. Elevated triglyceride was associated with treatment response in this exploratory analysis; however, further validation in larger cohorts is required."

Journal • Real-world evidence • Acne Vulgaris • Dermatitis • Dermatology • Dyslipidemia • Fatigue • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Pain • IL17A

Secukinumab Delays Time to Relapse in Patients with Polymyalgia Rheumatica After Treatment Discontinuation: Results from the Treatment-Free Follow-up Period in REPLENISH (ACR Convergence 2026) - No abstract available

Clinical • Giant Cell Arteritis • Immunology • Musculoskeletal Pain • Polymyalgia Rheumatica • Rheumatology

SECUKINUMAB-ASSOCIATED SARCOID-LIKE GRANULOMATOUS LYMPHADENOPATHY MIMICKING LYMPHOMA (CHEST 2026) - No abstract available

Hematological Malignancies • Lymphoma

Site-Specific Mucosal Candidiasis Associated With Bimekizumab, Secukinumab, and Guselkumab: A Pharmacosurveillance Analysis of the FDA Adverse Event Reporting System (FAERS) (ACR Convergence 2026) - No abstract available

Adverse events • Candidiasis

Resolution of Secukinumab/Guselkumab-Induced Long-Term Paradoxical Eczematous Eruptions After Switching to Tildrakizumab Treatment. (PubMed, J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatology • Immunology

Cross-Sectional Analysis of Biologic Use in the Treatment of Veterans With Hidradenitis Suppurativa. (PubMed, Fed Pract) - "Biologic medications, such as adalimumab, secukinumab, and bimekizumab, are currently the only medications approved by the US Food and Drug Administration for the treatment of hidradenitis suppurativa (HS)...Biologic prescriptions, including adalimumab and infliximab, were analyzed across varying patient demographics and characteristics...Biologic use in patients with HS was relatively low but higher or within the same range as previous studies. Understanding biologic prescription patterns offers potential to identify and improve access to underserved HS populations."

Journal • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Obesity

Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study. (PubMed, Psoriasis (Auckl)) - "Limitations include the retrospective single-center design, modest sample size, treatment imbalance, surrogate outcomes, and potential residual confounding. Compared with adalimumab, secukinumab was associated with more favorable longitudinal BMD trajectories and a bone turnover profile consistent with increased formation and reduced resorption in patients with psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Commentary on clinical characteristics and outcomes of paradoxical palmoplantar pustulosis during secukinumab therapy in biologic-naïve patients with plaque psoriasis: a retrospective case series. (PubMed, J Dermatolog Treat) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Psoriasis

Chronic active antibody mediated rejection treatment with IL-17Ai plus IL-6i in kidney transplant (TTS 2026) - "Secukinumab dosage was adjusted according to the scheme used in plaque psoriasis. Followed by IL-6i Tocilizumab (8mg/kg/month for 3 months) used as compassionate treatment for cAABMR during the COVID-19 pandemic; since standard treatment was unavailable at the time... In KTR with cAABMR it is feasible to increase allograft survival by inhibiting both IL-6 and IL-17A and theoretically decreasing tissue injury and microvascular inflammation by doing so. Our results should be confirmed in larger studies with higher statistic power. Therefore, intervention studies should be carried out under strict risk- benefit analysis to improve kidney allograft survival in patients with cAABMR."

Antibody-mediated Rejection • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Transplant Rejection • Transplantation • Tuberculosis • IL17A